share_log

NLS Pharmaceutics Analyst Ratings

NLS Pharmaceutics Analyst Ratings

NLS 藥學分析師評級
Benzinga ·  2023/09/14 19:58
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/14/2023 — Maxim Group Downgrades Buy → Hold
12/08/2022 387.75% Maxim Group → $4 Upgrades Hold → Buy
11/08/2022 — Maxim Group Downgrades Buy → Hold
09/06/2022 631.62% Laidlaw & Co. → $6 Initiates Coverage On → Buy
03/12/2021 1363.24% Brookline Capital → $12 Initiates Coverage On → Buy
03/03/2021 875.49% Maxim Group → $8 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變動 評級變動 之前/當前的評級
09/14/2023 — Maxim 集團 降級 買入 → 持有
2022 年 8 月 12 日 387.75% Maxim 集團 → 4 美元 升級 持有 → 買入
2022 年 8 月 11 日 — Maxim 集團 降級 買入 → 持有
09/06/2022 631.62% Laidlaw & Co. → 6 美元 啓動覆蓋範圍開啓 → 購買
2021 年 12 月 3 日 1363.24% 布魯克林資本 → 12 美元 啓動覆蓋範圍開啓 → 購買
03/03/2021 875.49% Maxim 集團 → 8 美元 啓動覆蓋範圍開啓 → 購買

What is the target price for NLS Pharmaceutics (NLSP)?

NLS Pharmaceutics（NLSP）的目標價格是多少？

The latest price target for NLS Pharmaceutics (NASDAQ: NLSP) was reported by Maxim Group on September 14, 2023. The analyst firm set a price target for $0.00 expecting NLSP to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.

Maxim集團於2023年9月14日公佈了NLS藥業（納斯達克股票代碼：NLSP）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計NLSP將在12個月內降至-100.00％（下行幅度可能爲-100.00％）。去年有3家分析公司公佈了評級。

What is the most recent analyst rating for NLS Pharmaceutics (NLSP)?

NLS Pharmacetics（NLSP）的最新分析師評級是多少？

The latest analyst rating for NLS Pharmaceutics (NASDAQ: NLSP) was provided by Maxim Group, and NLS Pharmaceutics downgraded their hold rating.

NLS Pharmacetics（納斯達克股票代碼：NLSP）的最新分析師評級由Maxim集團提供，NLS Pharmacetics下調了持倉評級。

When is the next analyst rating going to be posted or updated for NLS Pharmaceutics (NLSP)?

NLS Pharmacetics（NLSP）的下一次分析師評級何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NLS Pharmaceutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NLS Pharmaceutics was filed on September 14, 2023 so you should expect the next rating to be made available sometime around September 14, 2024.

分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與NLS Pharmacetics的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。NLS Pharmacetics的最後一次評級是在2023年9月14日提交的，因此你應該預計下一個評級將在2024年9月14日左右公佈。

Is the Analyst Rating NLS Pharmaceutics (NLSP) correct?

NLS Pharmacetics（NLSP）的分析師評級是否正確？

While ratings are subjective and will change, the latest NLS Pharmaceutics (NLSP) rating was a downgraded with a price target of $0.00 to $0.00. The current price NLS Pharmaceutics (NLSP) is trading at is $0.82, which is out of the analyst's predicted range.

儘管評級是主觀的，並且會發生變化，但最新的NLS Pharmactics（NLSP）評級被下調，目標股價爲0.00美元至0.00美元。NLS Pharmaceutics（NLSP）目前的交易價格爲0.82美元，超出了分析師的預測區間。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論